You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
TwinStrand's duplex sequencing correction technology can detect ultra-low frequency DNA mutations that are otherwise often obscured by technical noise.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
The firm signed a deal with Zotal to be exclusive Israeli distributor of the test, which measures proteins in patient blood to detect diabetic kidney disease.
Under the agreement, Genetron gains exclusive rights to develop and commercialize minimal residual disease assays using ImmuQuad's immunogenomics technology.
Under a licensing deal, Omixon will sell the AzureSeq-200 RT-PCR kit under its brand in Europe, the Middle East, and Africa.
Under the non-exclusive license, Quanterix will receive an initial license fee, milestone fees and launch milestones, and royalties.
The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.
Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.
The blood test will be available to specialty and primary care physicians across the US and Canada from LabCorp by early 2021.
Under the agreement, DiaSorin will make the test, which distinguishes between viral and bacterial infections, available on its Liaison analyzer platform.